JNJ-75348780 clinical trials
JNJ-75348780 is named as an intervention in 3 current clinical trials in our Spain, Australia, UK, China, Denmark, Taiwan, Israel, France, Belgium, Poland, Japan and South Korea registers. None are recruiting at the moment. All registered phases are Phase 1. The lead sponsor is Janssen Research & Development, LLC. The most-studied condition is Lymphoma, Non-Hodgkin.
How JNJ-75348780 works
All drug targets →- B-cell chronic lymphocytic leukemiaPhase 1
- Acute myeloid leukemiaPhase 1
- Myelodysplastic syndromePhase 1
- Non-Hodgkin lymphomaPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5314871, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for JNJ-75348780
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of JNJ-75348780
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
NCT06788509 · Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin
|
Phase 1 | By invitation | Janssen Research & Development, LLC | UK, China, France, Spain, Belgium, Denmark, Poland, Japan, South Korea, Taiwan, Australia, Israel |
|
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer
NCT06139406 · ClinicalTrials.gov ↗ · Lymphoma, Non-Hodgkin
|
Phase 1 | Active, closed | Janssen Research & Development, LLC | Spain, Denmark, Australia, Israel |
|
A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)
NCT06660563 · Lymphoma, Non-Hodgkin
|
Phase 1 | Active, closed | Janssen Research & Development, LLC | UK, China, Spain, Taiwan, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with JNJ-75348780
4 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Janssen Research & Development, LLC | 3 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about JNJ-75348780 trials
How many clinical trials are testing JNJ-75348780?
3 current trials in our Spain, Australia, UK, China, Denmark, Taiwan, Israel, France, Belgium, Poland, Japan and South Korea registers name JNJ-75348780 as a drug or biological intervention, as of the registry sync on 8 November 2026. Completed and withdrawn studies are not counted.
Are JNJ-75348780 trials recruiting patients?
Not at the moment. None of the 3 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Who sponsors JNJ-75348780 clinical trials?
The lead sponsor is Janssen Research & Development, LLC. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how JNJ-75348780 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how JNJ-75348780 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists JNJ-75348780 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 8 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.